Related Experiment Video

Updated: Aug 7, 2026

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

[Non-small cell lung cancer--immunocell BAK (BRM activated killer) therapy]

Takusaburo Ebina1

  • 1The Sendai Institute for Microbiology, Immunotherapy Center.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 15, 2006
PubMed

Insights

Immunosuppressed non-small cell lung cancer (NSCLC) patients with high IAP levels had shorter survival with BAK therapy. Immunoreactive NSCLC patients with low IAP levels showed significantly longer survival, indicating a potential biomarker.

Area of Science:

  • Oncology
  • Immunology

Context:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality.
  • Immunosuppression is a common comorbidity in advanced cancer patients, potentially affecting treatment outcomes.
  • Serum levels of Inducible Apoptosis Protein (IAP) may correlate with patient immune status and prognosis.

Purpose:

  • To evaluate the efficacy of BAK therapy in non-small cell lung cancer (NSCLC) patients based on their serum Inducible Apoptosis Protein (IAP) levels.
  • To determine if serum IAP levels can serve as a predictive biomarker for BAK therapy response in advanced NSCLC.

Summary:

  • This study included 14 immunosuppressed NSCLC outpatients (serum IAP > 580 microg/ml) and 26 immunoreactive NSCLC outpatients (serum IAP < 580 microg/ml).
  • Patients received BAK therapy on an outpatient basis.
  • Immunoreactive patients (low IAP) demonstrated a significantly longer mean survival (26.3 months) compared to immunosuppressed patients (high IAP) (5.2 months) (p<0.01).

Impact:

  • Serum IAP levels under 580 microg/ml may indicate a favorable response to BAK therapy in stage IV NSCLC patients.
  • BAK therapy shows a life-prolonging effect with no apparent adverse effects in advanced NSCLC.
  • The lungs' primary exposure to BAK via the bloodstream might contribute to the favorable clinical response observed in lung cancer patients.

More Related Videos

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...